EMT is a pivotal step in cancer progression driven by multiple signaling pathways, endowing cancer cells with invasive properties marked by upregulation of mesenchymal markers (vimentin, N-cadherin, fibronectin, type I collagen, laminin 5, MMPs) and downregulation of epithelial markers (E-cadherin, claudins, occludins, desmoplakin, type IV collagen, laminin 1) [87,88]. Here, CDH2 is linked to cancer.